Evolving targeted biologics against T cells, cytokines, and intracellular immune targets for multiple sclerosis with implications in other autoimmune neurologic diseases.

Over the last three decades, immunotherapies targeting T cells, cytokines, and intracellular molecules have been explored extensively in clinical trials in multiple sclerosis (MS). These studies resulted in the approval of several therapies for the t…

Preview only. Read the full abstract at the source